VTRS (viatris.com) Enterprise Value-to-Revenue Ratio

Official company branding of Viatris (VTRS)

Is it worth investing in the global distribution network of affordable medicines Viatris Inc. (VTRS)? The enterprise value-to-annual revenue multiple provides the answer, where 2338.69 serves as the base parameter value. Market capitalization relies on the recognition of legacy brands that generate passive income. Stable cash flows support the business while biosimilars develop, and total pharmacy coverage makes the company an indispensable supplier.

VTRS Viatris Corp: EV/Sales Multiple in the range 11/23/2025 - 11/20/2026

VTRS (Viatris Corp): analytical breakdowns and indicator data

- stock value and consensus price forecast:
- business market valuation indicators:
Fundamental company valuation:VTRS (viatris.com)
Manufactured products of Viatris Inc

The global scale of generic production and strict FDA oversight ensure the market resilience of Viatris Inc. (VTRS). This metric correlates the total enterprise value with sales volume, excluding the impact of debt load to assess the actual efficiency of revenue generation. Analyzing the enterprise value-to-revenue ratio helps determine whether the company's technological potential is overvalued relative to its current operating results.